saved
Request for Proposal
Status: RFP is Closed

New Drug Modality Targeting Immunosuppressive Cells

Request Number
RFP_2019_0042
Due Date
Apr 1
Program Manager

Opportunity

Licensing: Only drug modality

Joint research: Development modality with a unique evaluation system

Timeline

Joint research: Expecting, but not limited to, 1–3 years

Financials

To be discussed based on proposals

How to  Apply

Click on "Respond", complete the form to the extent possible, and submit along with other attachment files available. 

After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.

SOLUTION PROVIDER HELP DESK

If you have any questions or request, please feel free to contact us at: phd2@ninesigma.com
RFP was closed on
May 2019

RFP Title

 

New Drug Modality Targeting Immunosuppressive Cells
RFP Description

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) (“Client”), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality.

In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.

Focusing on cancer as its key area and considering the development of novel unique products to be its basic strategy, the Client decided to seek a partner with whom it can provide novel drugs to the market as soon as possible based on the above concept.

Key Success Criteria

Requirements for drug modality / evaluation system
The client seeks one of the following:

1. New drug modality

  • Modality: Low molecular compound, peptide, protein, antibody, nucleic acid
    • Ideally the proposal of peptide, protein, or antibody is combined with intracellular delivery technology.
  • Able to target immunosuppressive cells and modify/interfere with their functions or survival.
  • Ideally, the candidate has an in vitro evaluation system that meets the following requirement 2. in vitro evaluation system and the modality was discovered using that system.

2. In vitro evaluation system

  • Able to monitor the functions and survival of immunosuppressive cells, and evaluate the efficacy of the modality to the cellular targets.
Items to be Submitted

Anticipated Project Process

After the preliminary screening of documents, the Client will ask additional questions to promising proposals and conduct direct discussions to select candidates for the final selection. During the selection process, the Client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities. Specifics of any collaboration will be determined through consultation with the concerned parties. 

Notes on Response

Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.

Response evaluation

The client will evaluate all responses with the following criteria.

  • Overall scientific and technical merit
  • Approach to proof of concept or performance
  • Economic potential of concept
  • Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)
  • Potential for proprietary position
  • Respondents’ capability and related experiences  
Preferred Collaboration Types
Area of Interest